358 related articles for article (PubMed ID: 30191976)
1. Nicotinamide phosphoribosyl transferase regulates cell growth via the Sirt1/P53 signaling pathway and is a prognosis marker in colorectal cancer.
Pan JH; Zhou H; Zhu SB; Huang JL; Zhao XX; Ding H; Qin L; Pan YL
J Cell Physiol; 2019 Apr; 234(4):4385-4395. PubMed ID: 30191976
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.
Wang LF; Wang XN; Huang CC; Hu L; Xiao YF; Guan XH; Qian YS; Deng KY; Xin HB
Lipids Health Dis; 2017 Apr; 16(1):82. PubMed ID: 28449683
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells.
Thakur BK; Dittrich T; Chandra P; Becker A; Lippka Y; Selvakumar D; Klusmann JH; Reinhardt D; Welte K
Biochem Biophys Res Commun; 2012 Aug; 424(3):371-7. PubMed ID: 22728882
[TBL] [Abstract][Full Text] [Related]
4. A Nampt inhibitor FK866 mimics vitamin B3 deficiency by causing senescence of human fibroblastic Hs68 cells via attenuation of NAD(+)-SIRT1 signaling.
Song TY; Yeh SL; Hu ML; Chen MY; Yang NC
Biogerontology; 2015 Dec; 16(6):789-800. PubMed ID: 26330291
[TBL] [Abstract][Full Text] [Related]
5. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
Ogino Y; Sato A; Uchiumi F; Tanuma SI
Genomics; 2019 Dec; 111(6):1889-1895. PubMed ID: 30582964
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
[TBL] [Abstract][Full Text] [Related]
7. Targeting the NAD
Ye C; Qi L; Li X; Wang J; Yu J; Zhou B; Guo C; Chen J; Zheng S
Cell Commun Signal; 2020 Jan; 18(1):16. PubMed ID: 32005247
[TBL] [Abstract][Full Text] [Related]
8. Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells.
Ogino Y; Sato A; Kawano Y; Aoyama T; Uchiumi F; Tanuma SI
Anticancer Res; 2019 Dec; 39(12):6457-6462. PubMed ID: 31810909
[TBL] [Abstract][Full Text] [Related]
9. Resveratrol differentially regulates NAMPT and SIRT1 in Hepatocarcinoma cells and primary human hepatocytes.
Schuster S; Penke M; Gorski T; Petzold-Quinque S; Damm G; Gebhardt R; Kiess W; Garten A
PLoS One; 2014; 9(3):e91045. PubMed ID: 24603648
[TBL] [Abstract][Full Text] [Related]
10. The NAMPT/E2F2/SIRT1 axis promotes proliferation and inhibits p53-dependent apoptosis in human melanoma cells.
Zhao H; Tang W; Chen X; Wang S; Wang X; Xu H; Li L
Biochem Biophys Res Commun; 2017 Nov; 493(1):77-84. PubMed ID: 28919418
[TBL] [Abstract][Full Text] [Related]
11. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells.
Schuster S; Penke M; Gorski T; Gebhardt R; Weiss TS; Kiess W; Garten A
Biochem Biophys Res Commun; 2015 Mar; 458(2):334-40. PubMed ID: 25656579
[TBL] [Abstract][Full Text] [Related]
12. Nampt promotes osteogenic differentiation and lipopolysaccharide-induced interleukin-6 secretion in osteoblastic MC3T3-E1 cells.
He S; Zhang H; Lu Y; Zhang Z; Zhang X; Zhou N; Hu Z
Aging (Albany NY); 2021 Feb; 13(4):5150-5163. PubMed ID: 33535169
[TBL] [Abstract][Full Text] [Related]
13. Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells.
Thakur BK; Dittrich T; Chandra P; Becker A; Kuehnau W; Klusmann JH; Reinhardt D; Welte K
Int J Cancer; 2013 Feb; 132(4):766-74. PubMed ID: 22815158
[TBL] [Abstract][Full Text] [Related]
14. NAMPT pathway is involved in the FOXO3a-mediated regulation of GADD45A expression.
Thakur BK; Lippka Y; Dittrich T; Chandra P; Skokowa J; Welte K
Biochem Biophys Res Commun; 2012 Apr; 420(4):714-20. PubMed ID: 22430142
[TBL] [Abstract][Full Text] [Related]
15. Restoring NAD
Katayoshi T; Nakajo T; Tsuji-Naito K
J Photochem Photobiol B; 2021 Aug; 221():112238. PubMed ID: 34130091
[TBL] [Abstract][Full Text] [Related]
16. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
Okumura S; Sasaki T; Minami Y; Ohsaki Y
J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
[TBL] [Abstract][Full Text] [Related]
17. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
Cea M; Cagnetta A; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Roccaro A; Sacco A; Calimeri T; Cottini F; Jakubikova J; Kong SY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
Blood; 2012 Oct; 120(17):3519-29. PubMed ID: 22955917
[TBL] [Abstract][Full Text] [Related]
18. Nicotinamide phosphoribosyltransferase postpones rat bone marrow mesenchymal stem cell senescence by mediating NAD
Pi C; Yang Y; Sun Y; Wang H; Sun H; Ma M; Lin L; Shi Y; Li Y; Li Y; He X
Aging (Albany NY); 2019 Jun; 11(11):3505-3522. PubMed ID: 31175267
[No Abstract] [Full Text] [Related]
19. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
[TBL] [Abstract][Full Text] [Related]
20. On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells.
Gehrke I; Bouchard ED; Beiggi S; Poeppl AG; Johnston JB; Gibson SB; Banerji V
Clin Cancer Res; 2014 Sep; 20(18):4861-72. PubMed ID: 25172933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
